Asthma Plus Migraine in Childhood and Adolescence: Prophylactic Benefits with Leukotriene Receptor Antagonist

Carvalho, Diana Paula de Souza Rêgo Pinto; Fragoso, Yára Dadalti; Coelho, Fernando Morgadinho Santos; Pereira, Mariana Machado

doi:10.1046/j.1526-4610.2002.02236.x

Cited by 10 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…108). Montelukast is a leukotriene receptor antagonist with demonstrated efficacy in two small, open label trials for migraine prophylaxis (Refs 109, 110). This drug was not successful in a larger, double-blind study (Ref.…”

Section: Mast Cell Degranulationmentioning

confidence: 99%

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

Raddant

Russo

2011

Expert Rev. Mol. Med.

170

153

View full text Add to dashboard Cite

Over the past two decades, a convergence of basic and clinical evidence has established the neuropeptide calcitonin-gene-related peptide (CGRP) as a key player in migraine. Although CGRP is a recognised neuromodulator of nociception, its mechanism of action in migraine remains elusive. In this review, we present evidence that led us to propose that CGRP is well poised to enhance neurotransmission in migraine by both peripheral and central mechanisms. In the periphery, it is thought that local release of CGRP from the nerve endings of meningeal nociceptors following their initial activation by cortical spreading depression is critical for the induction of vasodilation, plasma protein extravasation, neurogenic inflammation and the consequential sensitisation of meningeal nociceptors. Mechanistically, we propose that CGRP release can give rise to a positive-feedback loop involved in localised increased synthesis and release of CGRP from neurons and a CGRP-like peptide called procalcitonin from trigeminal ganglion glia. Within the brain, the wide distribution of CGRP and CGRP receptors provides numerous possible targets for CGRP to act as a neuromodulator.

show abstract

Section: Mast Cell Degranulationmentioning

confidence: 99%

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

Raddant

Russo

2011

Expert Rev. Mol. Med.

170

153

View full text Add to dashboard Cite

show abstract

“…31 In 2002, de Souza Carvalho et al studied 6 children and adolescents with asthma and migraine and noted that treatment with montelukast at 5 mg daily for 24 weeks lowered the number of reported asthma attacks and significantly decreased the frequency of headaches compared with baseline. 32 However, other studies failed to confirm those results. 33,34 Two other promising studies on immunotherapy for migraine were published in 2011.…”

Section: Discussionmentioning

confidence: 98%

Is There An Association between Migraine and Allergic Rhinitis?

et al. 2017

View full text Add to dashboard Cite

We conducted a prospective study to evaluate nasal signs and symptoms and to perform allergen-specific immunoglobulin E (IgE) testing to investigate the relationship between migraine and allergic rhinitis. Our study group consisted of 40 patients diagnosed with migraine-22 men and 18 women, aged 21 to 38 years (mean: 25.7). We compared their findings with a control group of 40 healthy adults-15 men and 25 women, aged 19 to 36 years (mean: 25.1). Allergen-specific IgE measurements were obtained with six groups of allergens: fungi, grass pollens, tree pollens, wild herbs, house dust mite 1, and house dust mite 2. We found no significant difference between the migraine patients and the controls in the incidence of nasal signs and symptoms (i.e., discharge, congestion, itching, and sneezing) or inferior turbinate signs (i.e., color and edema). According to the IgE assays, 14 migraine patients (35.0%) were sensitized to one or more allergens, compared with 11 of the controls (27.5%); the difference was not statistically significant. Sensitization was highest for the grass pollens panel in both groups. Even though we did not find an association between migraine and allergic rhinitis, the recent literature supports a correlation between migraine and atopy. The two conditions share common neural pathways and common mediators, and they can be linked statistically in patients and their families. A pathophysiologic association between the two conditions seems more likely than an etiologic association. In this regard, future efforts could be focused on the determination of atopy in migraine patients and the therapeutic implications of this diagnosis.

show abstract

“…Montelukast has been evaluated through a multicenter, double-blind placebo-controlled study, 126 two case-control studies, 127 128 and four case reports. 129 130 131 132 The multicenter, double-blind, placebo-controlled study showed that this drug was not more effective than placebo. The open case studies demonstrated drug effectiveness and there was also a therapeutic response in the case reports.…”

Section: Other Drugsmentioning

confidence: 99%

Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Migraine affects 1 billion people worldwide and > 30 million Brazilians; besides, it is an underdiagnosed and undertreated disorder. Objective The need to disseminate knowledge about the prophylactic treatment of migraine is known, so the Brazilian Headache Society (SBCe, in the Portuguese acronym) appointed a committee of authors with the objective of establishing a consensus with recommendations on the prophylactic treatment of episodic migraine based on articles from the world literature as well as from personal experience. Methods Meetings were held entirely online, with the participation of 12 groups that reviewed and wrote about the pharmacological categories of drugs and, at the end, met to read and finish the document. The drug classes studied in part II of this Consensus were: antihypertensives, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, calcium channel blockers, other drugs, and rational polytherapy. Results From this list of drugs, only candesartan has been established as effective in controlling episodic migraine. Flunarizine, venlafaxine, duloxetine, and pizotifen were defined as likely to be effective, while lisinopril, enalapril, escitalopram, fluvoxamine, quetiapine, atorvastatin, simvastatin, cyproheptadine, and melatonin were possibly effective in prophylaxis of the disease. Conclusions Despite an effort by the scientific community to find really effective drugs in the treatment of migraine, given the large number of drugs tested for this purpose, we still have few therapeutic options.

show abstract

Asthma Plus Migraine in Childhood and Adolescence: Prophylactic Benefits with Leukotriene Receptor Antagonist

Cited by 10 publications

References 9 publications

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation

Is There An Association between Migraine and Allergic Rhinitis?

Consensus of the Brazilian Headache Society (SBCe) for prophylactic treatment of episodic migraine: part II

Contact Info

Product

Resources

About